- Delic is committed to bringing science-backed benefits to as many people as possible while also changing the narrative around psychedelics
- It seeks to achieve this through education, products and services, and research on psychedelics
- So far, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patients
- Delic recognizes the potential of psychedelics and their application in therapeutics, hence its investment in research, civic education, and service delivery in this sector
For many years, psychedelic drugs were frowned upon by society. This, along with psychedelics’ widespread popularity as recreational drugs in the 1960s and 70s, led to them being classified as a Schedule 1 controlled substance. Unfortunately, it only tainted their image further (
https://ibn.fm/KukAl).
Fast forward to 2022, and the conversation around psychedelics is changing. Experts have highlighted the products’ usefulness beyond simply being recreational drugs. Most importantly, they have highlighted psychedelics’ potential for treating conditions such as anxiety, depression, and even substance abuse issues.
One company that has been aggressive at pushing for psychedelics and leading the psychedelic wellness campaign is
Delic Holdings (CSE: DELC) (OTCQB: DELCF). Founded in 2019, the company is committed to bringing science-backed benefits to as many people as possible while changing the narrative surrounding psychedelics.
While pushing its products and services in the market, Delic’s management understands that it might not be enough if all the conversations surrounding psychedelics are to get bigger and more mainstream. As such, the company is committed to educating its audience, a task that is executed by the Delic media arm.
Delic leverages digital platforms such as
Reality Sandwich, a digital lifestyle magazine, coupled with Meet Delic, an annual wellness and business summit, and even
Delic Radio, all of which provide a wealth of information that helps demystify psychedelics and educate people on its benefits in the treatment of mental health conditions.
Fifty million people in the United States are addicted to some tobacco products. For context, in the United States, over 480,000 people die from cigarette smoking, representing one in every five deaths in the country (
https://ibn.fm/n8Hhh).
The company believes that the quality of life for many individuals dealing with mental health issues can be improved significantly through the use of psychedelic compounds.
Already, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patients. For example, 80% of terminally ill individuals who took psilocybin experienced significant reductions in depression and anxiety. Ketamine, on the other hand, has been shown to significantly reduce suicidal thoughts to the point where it received FDA approval back in 2019.
Delic believes there is tremendous potential in psychedelics, which is why the company is a leader in the industry and shaping the conversation around these medicines, educating more people on their usage, and conducting further research to explore their full potential. But, more importantly, Delic is looking to capitalize on a largely untapped market with tremendous potential for growth.
As interest in the potential of psychedelics for therapeutic applications grows, Delic is at the forefront, not just offering the product but also exploring what psychedelics can do and educating society on its potential. By doing so, it is pushing the whole industry forward, demystifying psychedelics and creating value for its shareholders.
For more information, visit the company’s website at
www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at
https://ibn.fm/DELCF
